Joan Cao

1.6k total citations · 1 hit paper
21 papers, 1.3k citations indexed

About

Joan Cao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Joan Cao has authored 21 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Infectious Diseases. Recurrent topics in Joan Cao's work include HIV Research and Treatment (5 papers), Cancer-related Molecular Pathways (5 papers) and HIV/AIDS drug development and treatment (5 papers). Joan Cao is often cited by papers focused on HIV Research and Treatment (5 papers), Cancer-related Molecular Pathways (5 papers) and HIV/AIDS drug development and treatment (5 papers). Joan Cao collaborates with scholars based in United States, United Kingdom and South Korea. Joan Cao's co-authors include David C. Spink, Carrie L. Hayes, Thomas R. Sutter, Barbara C. Spink, Nigel J. Walker, Wade Blair, Amy K. Patick, Jason Isaacson, Manos Perros and Hua Wu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Cancer Research.

In The Last Decade

Joan Cao

20 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1.

1996 543 citations Carrie L. Hayes, David C. Spink et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joan Cao United States	13	512	317	312	280	269	21	1.3k
Barbara A. Domin United States	20	501 1.0×	82 0.3×	87 0.3×	193 0.7×	181 0.7×	31	1.1k
Scott Heyward United States	22	738 1.4×	87 0.3×	543 1.7×	378 1.4×	85 0.3×	48	1.7k
Véronique Bourgarel‐Rey France	22	526 1.0×	73 0.2×	54 0.2×	69 0.2×	47 0.2×	30	1.1k
Hans Jörg Hacker Germany	22	516 1.0×	27 0.1×	97 0.3×	96 0.3×	138 0.5×	46	1.5k
Marco H. Hofmann Austria	13	489 1.0×	48 0.2×	36 0.1×	229 0.8×	96 0.4×	41	953
Nathan A. Lack Türkiye	22	668 1.3×	13 0.0×	246 0.8×	102 0.4×	166 0.6×	55	1.4k
E Schneider United States	17	1.0k 2.0×	31 0.1×	56 0.2×	63 0.2×	175 0.7×	21	1.8k
Scott Cuthill Sweden	18	721 1.4×	20 0.1×	204 0.7×	87 0.3×	12 0.0×	29	1.4k
Sue Chow Canada	19	700 1.4×	25 0.1×	73 0.2×	25 0.1×	46 0.2×	32	1.2k

Countries citing papers authored by Joan Cao

Since Specialization

Citations

This map shows the geographic impact of Joan Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan Cao more than expected).

Fields of papers citing papers by Joan Cao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan Cao. The network helps show where Joan Cao may publish in the future.

Co-authorship network of co-authors of Joan Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Joan Cao. A scholar is included among the top collaborators of Joan Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan Cao. Joan Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cao, Joan, Zhou Zhu, Hui Wang, et al.. (2019). Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer. Oncogene. 38(21). 4125–4141. 30 indexed citations

Wei, Ping, Ming Qiu, Nathan Lee, et al.. (2015). Abstract 764: Rational combination of PF-06463922 (next-generation ALK inhibitor) with PI3K pathway inhibitors overcomes ALKi resistance in EML4-ALK+ NSCLC models. Cancer Research. 75(15_Supplement). 764–764. 4 indexed citations

Koehler, María, Todd VanArsdale, David J. Shields, et al.. (2014). Mechanism of Action for Combined CDK4/6 and Er Inhibition in ER Positive Breast Cancer. Annals of Oncology. 25. i21–i21. 5 indexed citations

Lee, Nathan V., Jing Yuan, Joan Cao, et al.. (2014). Abstract LB-136: Mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancer. Cancer Research. 74(19_Supplement). LB–136. 3 indexed citations

Pavlı́c̀ek, Adam, Maruja E. Lira, Nathan V. Lee, et al.. (2013). Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871). Molecular Cancer Therapeutics. 12(12). 2929–2939. 31 indexed citations

Huang, Donghui, Dong‐Wan Kim, Αthanasios Kotsakis, et al.. (2013). Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Genomics. 102(3). 157–162. 34 indexed citations

Fang, Douglas D., Cathy C. Zhang, Yin Gu, et al.. (2013). Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation. PLoS ONE. 8(6). e67258–e67258. 33 indexed citations

Fang, Douglas D., Joan Cao, Jitesh P. Jani, et al.. (2013). Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line. Frontiers of Medicine. 7(4). 462–476. 15 indexed citations

Lee, Nathan V., Joan Cao, Stephen Huang, et al.. (2013). Abstract 4464: Elucidation of crizotinib resistance in NCI-H3122 and strategies to circumvent bypass resistance.. Cancer Research. 73(8_Supplement). 4464–4464. 1 indexed citations

10.

Hook, Kenneth E., Maruja E. Lira, Keith A. Ching, et al.. (2012). An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735. Molecular Cancer Therapeutics. 11(3). 710–719. 77 indexed citations

11.

Blair, Wade, Chris Pickford, S.L. Irving, et al.. (2010). HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention. PLoS Pathogens. 6(12). e1001220–e1001220. 241 indexed citations

12.

Fang, Douglas D., Yin Gu, Konstantinos Tsaparikos, et al.. (2010). Abstract 4483: Establishing patient-derived colorectal cancer stem cell models with a PIK3CA mutation for the development of inhibitory drugs as targeted therapies. Cancer Research. 70(8_Supplement). 4483–4483. 1 indexed citations

13.

Yuan, Jing, Adam Pavlı́c̀ek, Keith A. Ching, et al.. (2010). Abstract LB-302: Activity of PF-04691502, A dual PI3K/mTOR inhibitor in breast cancer cell lines and models discriminates between ER, PR and HER2 positive and negative segments. Cancer Research. 70(8_Supplement). LB–302. 1 indexed citations

14.

Blair, Wade, Joan Cao, Juin Fok‐Seang, et al.. (2009). New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation. Antimicrobial Agents and Chemotherapy. 53(12). 5080–5087. 50 indexed citations

15.

Blair, Wade, Joan Cao, Lynn Jackson, et al.. (2007). Identification and Characterization of UK-201844, a Novel Inhibitor That Interferes with Human Immunodeficiency Virus Type 1 gp160 Processing. Antimicrobial Agents and Chemotherapy. 51(10). 3554–3561. 10 indexed citations

16.

Cao, Joan, Jason Isaacson, Amy K. Patick, & Wade Blair. (2005). High-Throughput Human Immunodeficiency Virus Type 1 (HIV-1) Full Replication Assay That Includes HIV-1 Vif as an Antiviral Target. Antimicrobial Agents and Chemotherapy. 49(9). 3833–3841. 29 indexed citations

17.

Blair, Wade, Jason Isaacson, Xinqiang Li, et al.. (2004). A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors. Antiviral Research. 65(2). 107–116. 33 indexed citations

18.

Pang, Shaokun, Joan Cao, Barbara H. Katz, et al.. (1999). Inductive and inhibitory effects of non-ortho-substituted polychlorinated biphenyls on estrogen metabolism and human cytochromes P450 1A1 and 1B1. Biochemical Pharmacology. 58(1). 29–38. 61 indexed citations

19.

Spink, David C., Barbara C. Spink, Joan Cao, et al.. (1997). Induction of cytochrome P450 1B1 and catechol estrogen metabolism in ACHN human renal adenocarcinoma cells. The Journal of Steroid Biochemistry and Molecular Biology. 62(2-3). 223–232. 69 indexed citations

20.

Hayes, Carrie L., David C. Spink, Barbara C. Spink, et al.. (1996). 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1.. Proceedings of the National Academy of Sciences. 93(18). 9776–9781. 543 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact